Chen KY, Borglund EM, Postema EC, Dunn AG, Bourgeois FT. Reporting of clinical trial safety results in ClinicalTrials.gov for FDA-approved drugs: a cross-sectional analysis. Clin Trials. 2022;19:442–51. https://doi.org/10.1177/17407745221093567.

Article  PubMed  PubMed Central  Google Scholar 

Maggi CB, Griebeler IH, Dal Pizzol TDS. Information on adverse events in randomised clinical trials assessing drug interventions published in four medical journals with high impact factors. Int J Risk Saf Med. 2014;26:9–22. https://doi.org/10.3233/JRS-140609.

Article  PubMed  Google Scholar 

Péron J, Maillet D, Gan HK, Chen EX, You B. Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review. JCO. 2013;31:3957–63. https://doi.org/10.1200/JCO.2013.49.3981.

Article  Google Scholar 

Hum SW, Golder S, Shaikh N. Inadequate harms reporting in randomized control trials of antibiotics for pediatric acute otitis media: a systematic review. Drug Saf. 2018;41:933–8. https://doi.org/10.1007/s40264-018-0680-0.

Article  PubMed  CAS  Google Scholar 

Phillips R, Hazell L, Sauzet O, Cornelius V. Analysis and reporting of adverse events in randomised controlled trials: a review. BMJ Open. 2019;9:e024537. https://doi.org/10.1136/bmjopen-2018-024537.

Article  PubMed  PubMed Central  Google Scholar 

Madi K, Flumian C, Olivier P, Sommet A, Montastruc F. Quality of reporting of adverse events in clinical trials of covid-19 drugs: systematic review. BMJ Med. 2023;2:e000352. https://doi.org/10.1136/bmjmed-2022-000352.

Article  PubMed  PubMed Central  Google Scholar 

Ioannidis JPA, Evans SJW, Gøtzsche PC, O’Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141(10):781–8. https://doi.org/10.7326/0003-4819-141-10-200411160-00009.

Article  PubMed  Google Scholar 

Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, et al. CONSORT harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials. BMJ. 2023. https://doi.org/10.1136/bmj-2022-073725.

Article  PubMed  Google Scholar 

Food and Drug Administration. Safety reporting requirements for INDs and BA/BE studies: Guidance for industry and Investigators. Published online December 2012. https://www.fda.gov/media/79394/download. Accessed 4 Apr 2025.

US Department of Health and Human Services. Sponsor responsibilities—safety reporting requirements and safety assessment for IND and bioavailability/bioequivalence studies guidance for industry draft guidance. Food and Drug Administration; 2021. https://www.fda.gov/media/150356/download. Accessed 4 Apr 2025.

Willame C, Dodd C, Durán C, Elbers R, Gini R, Bartolini C, et al. Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study. Vaccine. 2023;41:251–62. https://doi.org/10.1016/j.vaccine.2022.11.031.

Article  PubMed  CAS  Google Scholar 

Rasmussen TA, Jorgensen MRS, Bjerrum S, Jensen-Fangel S, Stovring H, Ostergaard L, et al. Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study. BMJ. 2012;345:e5823–e5823. https://doi.org/10.1136/bmj.e5823.

Article  PubMed  PubMed Central  Google Scholar 

Black SB, Law B, Chen RT, Dekker CL, Sturkenboom M, Huang W-T, et al. The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety. Vaccine. 2021;39:2712–8. https://doi.org/10.1016/j.vaccine.2021.03.016.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Moll K, Lufkin B, Fingar KR, Ke Zhou C, Tworkoski E, Shi C, et al. Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019–2020. Vaccine. 2023;41:333–53. https://doi.org/10.1016/j.vaccine.2022.11.003.

Article  PubMed  Google Scholar 

Waterhouse B, Hartford A, Mukhopadhyay S, Ferguson R, Hendrickson BA. Using the Bayesian detection of potential risk using inference on blinded safety data (BDRIBS) method to support the decision to refer an event for unblinded evaluation. Pharm Stat. 2022;21:372–85. https://doi.org/10.1002/pst.2175.

Article  PubMed  Google Scholar 

Ball G. Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Contemp Clin Trials. 2011;32:S11–7. https://doi.org/10.1016/j.cct.2011.05.008.

Article  PubMed  Google Scholar 

Schnell PM, Ball G. A Bayesian exposure-time method for clinical trial safety monitoring with blinded data. Ther Innov Regul Sci. 2016;50:833–8. https://doi.org/10.1177/2168479016656702.

Article  PubMed  Google Scholar 

Ball G, Schnell PM. Blinded safety signal monitoring for the FDA IND reporting final rule. In: Lin J, Wang B, Hu X, Chen K, Liu R, editors. Statistical applications from clinical trials and personalized medicine to finance and business analytics. Cham: Springer International Publishing; 2016. p. 201–11. https://doi.org/10.1007/978-3-319-42568-9_17.

Mukhopadhyay S, Waterhouse B, Hartford A. Bayesian detection of potential risk using inference on blinded safety data. Pharm Stat. 2018;17:823–34. https://doi.org/10.1002/pst.1898.

Article  PubMed  Google Scholar 

Brock K, Chen C, Ho S, Fuller G, Woolfolk J, McShea C, et al. A Bayesian method for safety signal detection in ongoing blinded randomised controlled trials. Pharm Stat. 2023;22:378–95. https://doi.org/10.1002/pst.2278.

Article  PubMed  Google Scholar 

Lin L-A, Zhan Y, Li H, Yuan SS, Ball G, Wang W. Bridging blinded and unblinded analysis for ongoing safety monitoring and evaluation. Contemp Clin Trials. 2019;83:81–7. https://doi.org/10.1016/j.cct.2019.06.022.

Article  PubMed  Google Scholar 

Ewer MS, Herson J. Cardiovascular adverse events in oncology trials: understanding and appreciating the differences between clinical trial data and real-world reports. Cardio-Oncol. 2022;8:13. https://doi.org/10.1186/s40959-022-00139-w.

Article  Google Scholar 

Hendrickson BA, McShea C, Ball G, Talbot S. How aggregate safety assessment planning supports investigational new drug safety reporting decisions. Ther Innov Regul Sci. 2024;58:579–90. https://doi.org/10.1007/s43441-024-00634-5.

Article  PubMed  Google Scholar 

ClinicalTrials.gov. About ClinicalTrials.gov. ClinicalTrials.gov; 2024. https://clinicaltrials.gov/about-site/about-ctg. Accessed 4 Apr 2025.

21 USC 355a. Food and Drug Administration Modernization Act (FDAMA) of 1997 (Public Law 105-115). U.S. Food and Drug Administration; 1997.

Gresham G, Meinert JL, Gresham AG, Piantadosi S, Meinert CL. Update on the clinical trial landscape: analysis of ClinicalTrials.gov registration data, 2000–2020. Trials. 2022;23:858. https://doi.org/10.1186/s13063-022-06569-2.

Article  PubMed  PubMed Central  Google Scholar 

National Institutes of Health. NIH policy on the dissemination of NIH-funded clinical trial information (Notice No. NOT-OD-16-149). 2016. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-16-149.html. Accessed 30 Apr 2025.

European Medicines Agency. Clinical Trials Regulation (Regulation (EU) No 536/2014). 2014. https://health.ec.europa.eu/document/download/f724d198-9ec8-4cad-9ce7-b6d2ac1ec44e_en. Accessed 4 Apr 2025.

Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397:475–86. https://doi.org/10.1016/S0140-6736(21)00126-4.

Article  PubMed  CAS  Google Scholar 

Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397:487–98. https://doi.org/10.1016/S0140-6736(21)00125-2.

Article  PubMed  CAS  Google Scholar 

Warren RB, Blauvelt A, Bagel J, Papp KA, Yamauchi P, Armstrong A, et al. Bimekizumab versus Adalimumab in plaque psoriasis. N Engl J Med. 2021;385:130–41. https://doi.org/10.1056/NEJMoa2102388.

Article  PubMed  CAS  Google Scholar 

Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219–29. https://doi.org/10.1056/NEJMoa2025845.

Article  PubMed  CAS  Google Scholar 

Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252–63. https://doi.org/10.1056/NEJMoa2110956.

Article  PubMed  CAS  Google Scholar 

Burmester GR, Kremer JM, Van Den Bosch F, Kivitz A, Bessette L, Li Y, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:2503–12. https://doi.org/10.1016/S0140-6736(18)31115-2.

Article  PubMed  CAS